<DOC>
	<DOCNO>NCT01732107</DOCNO>
	<brief_summary>This trial assess 6-month complete response rate toxicity profile oral dovitinib therapy BCG-refractory urothelial carcinoma patient tumor FGFR3 mutation over-expression ineligible refuse cystectomy .</brief_summary>
	<brief_title>Dovitinib BCG Refractory Urothelial Carcinoma With FGFR3 Mutations Over-expression</brief_title>
	<detailed_description>OUTLINE : This multi-center study . - Dovitinib administer 500mg orally 5 day , 2 day dose schedule . Day 12 assessment intend perform last dosing day 2nd week cycle 1 cycle 2 day 26 assessment intend perform last dosing day 4th week cycle 1 cycle 2 . - Standard Care : Cystoscopy tumor biopsy , bladder biopsy , urine cytology - Physician discretion : Anti-emetic medication and/or colony stimulating growth factor ECOG performance status 0 - 2 Hematopoietic : - White blood cell count ( WBC ) &gt; 3.0 K/mm3 - Absolute neutrophil count ( ANC ) ≥ 1.5 K/mm3 - Platelets ≥ 100 K/mm3 - Hemoglobin ( Hgb ) ≥ 9 g/dL Hepatic : - Serum total bilirubin : ≤ 1.5 x Upper limit normal ( ULN ) - Alanine aminotransferase ( ALT ) Aspartate aminotransferase ( AST ) ≤ 3.0 x ULN Renal : - Serum creatinine ≤ 1.5 x ULN serum creatinine &gt; 1.5 - 3 x ULN calculate creatinine clearance ( CrCl ) ≥ 30 mL/min use Cockcroft-Gault equation Cardiovascular : No impaired cardiac function clinically significant cardiac disease , include follow : - History presence serious uncontrolled ventricular arrhythmia - Clinically significant rest bradycardia - LVEF assess 2-D echocardiogram ( ECHO ) &lt; 50 % low limit normal ( whichever high ) multiple gated acquisition scan ( MUGA ) , &lt; 45 % low limit normal ( whichever high ) - Myocardial Infarction ( MI ) , severe/unstable angina , Coronary Artery Bypass Graft ( CABG ) , Congestive Heart Failure ( CHF ) , Cerebrovascular Accident ( CVA ) , Transient Ischemic Attack ( TIA ) , Pulmonary Embolism ( PE ) within 6 month prior start study drug</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<criteria>Histologically confirm early stage urothelial carcinoma bladder define Ta , T1 , Tis stage . Presence either FGFR3 mutation FGFR3 overexpression within bladder tumor tissue . Documented BCGrefractory disease define failure achieve tumor free state least 2 prior induction course intravesical BCG therapy . Medically unfit undergo cystectomy electively choose forego cystectomy Patients give write informed consent obtain accord local guideline Patients muscleinvasive ( i.e . T2 , T3 , T4 ) , locally advance nonresectable , metastatic urothelial carcinoma assess baseline radiographic imaging obtain within 28 day prior study registration . Patients concurrent upper urinary tract ( i.e . ureter , renal pelvis ) noninvasive urothelial carcinoma . Patients another primary malignancy within 3 year prior start study drug , exception adequately treat insitu carcinoma uterine cervix , clinically localized prostate cancer , biochemically relapse nonmetastatic prostate cancer ( i.e. , PSA disease ) , skin cancer ( basal cell carcinoma , squamous cell carcinoma , nonmelanomatous skin cancer ) Patients receive last administration anticancer therapy include chemotherapy , immunotherapy , monoclonal antibody ≤ 4 week prior start study drug , recover side effect therapy Patients receive prior VEGFRtargeted FGFRtargeted agent ( i.e. , sunitinib , pazopanib , sorafenib , bevacizumab , axitinib , etc. ) . Patients radiotherapy ≤ 4 week prior start study drug , recover radiotherapy toxicity Patients undergone major surgery ( e.g . intrathoracic , intraabdominal intrapelvic ) , open biopsy significant traumatic injury ≤ 4 week prior start study drug , patient minor procedure ( i.e. , TURBT ) , percutaneous biopsy placement vascular access device ≤ 1 week prior start study drug , recover side effect procedure injury Uncontrolled hypertension define systolic blood pressure ( SBP ) ≥ 160 mm Hg and/or iastolic blood pressure ( DBP ) ≥ 100 mm Hg , without antihypertensive medication ( ) Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption dovitinib ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) Cirrhosis , chronic active hepatitis chronic persistent hepatitis Known diagnosis human immunodeficiency virus ( HIV ) infection ( HIV test mandatory ) Patients currently receive anticoagulation treatment therapeutic dos warfarin . Fulldose anticoagulation low molecular weight heparin permit . Other concurrent severe and/or uncontrolled concomitant medical condition ( e.g. , active uncontrolled infection , uncontrolled diabetes ) could cause unacceptable safety risk compromise compliance protocol Pregnant breastfeed woman Women childbearing potential , biologically able conceive , employ two form highly effective contraception . Highly effective contraception must use throughout trial 8 week last dose study drug ( e.g . male condom spermicidal ; diaphragm spermicide ; intrauterine device ) . Oral , implantable , injectable contraceptive may affect cytochrome P450 interaction consider effective study . Women childbearing potential , define sexually mature woman undergone hysterectomy naturally postmenopausal least 12 consecutive month ( i.e. , menses time precede 12 consecutive month ) , must negative serum pregnancy test ≤ 14 day prior start study drug . Fertile male willing use contraception , state Patients unwilling unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Dovitinib</keyword>
	<keyword>FGFR3 Mutations</keyword>
	<keyword>BCG-Refractory Urothelial Carcinoma</keyword>
</DOC>